Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Schedules,Therapeutic_group
Boehringer Ingelheim,Empagliflozin,"Chronic heart failure, NYHA II-IV and LVEF ≤40%",Empagliflozin (Jardiance®),Community and Hospital,Cardiovascular System
